Trials / Completed
CompletedNCT00455728
A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders
International Cooperative Growth Study (iNCGS) Post Marketing Surveillance Program for NutropinAq® [Somatropin (rDNA Origin) Injection]
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,690 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, open label, observational, post marketing surveillance study of NutropinAq® in Austria, France, Germany, Italy, Spain, Romania and United Kingdom to collect long-term safety and effectiveness information on NutropinAq® during treatment of paediatric growth disorders.
Detailed description
The objective of this study is to collect long term safety and effectiveness information on Ipsen's growth hormone (GH) NutropinAq® regarding treatment of paediatric growth disorders for which GH is indicated.
Conditions
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2007-04-04
- Last updated
- 2019-01-07
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00455728. Inclusion in this directory is not an endorsement.